Three Rivers Pharmaceuticals, LLC Protects Its Intellectual Property
Posted on: Wednesday, 6 June 2007, 15:00 CDT
CRANBERRY TOWNSHIP, Pa., June 6 /PRNewswire/ -- Three Rivers Pharmaceuticals, LLC, a leading specialty drug manufacturer today announced that it has sued Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited for infringement of Three Rivers' United States Patent No. 6,720,000. The '000 patent is directed to a new and important process for producing ribavirin pellets using wet granulation. Ribavirin is a synthetic nucleoside analog with broad spectrum antiviral properties used to treat patients with Hepatitis C and other viral infections.
The lawsuit against Zydus and Cadila, now pending in the United States District Court for the Eastern District of Virginia, seeks to enjoin those defendants from making, selling or importing finished dosage forms of ribavirin believed to be made by Three Rivers' patented process.
"We had hoped to confirm Zydus' and Cadila's respect of our intellectual property without the need for litigation," said Donald Kerrish, Three Rivers' President and CEO, "but they refused to provide us with any meaningful assurance that Zydus and Cadila had not used and would not use our patented process."
Three Rivers Pharmaceuticals is a privately held company headquartered in Cranberry Township, Pennsylvania and focuses in specialized therapies. Ribasphere(R), Three Rivers' ribavirin drug product produced by the '000 patent process, was approved by the U.S. Food & Drug Administration in April 2004.
Three Rivers Pharmaceuticals, LLC
CONTACT: Jen Roche of Three Rivers Pharmaceuticals, LLC,+1-724-778-6015
Web site: http://www.3riverspharma.com/
Source: PRNewswire
Related Articles
- Three Rivers Pharmaceuticals(R), LLC Obtains Additional Commercial Rights to Infergen(R) From Amgen Inc.
- Valeant Pharmaceuticals Completes Divestment of Hep-C Drug Infergen(R) to Three Rivers Pharmaceuticals(R), LLC
- Three Rivers Pharmaceuticals(R), LLC Acquires Hepatitis C Drug Infergen(R) From Valeant Pharmaceuticals
- Valeant Pharmaceuticals Sells Hep-C Drug Infergen(R) to Three Rivers Pharmaceuticals(R), LLC for $91 Million
- New River Pharmaceuticals Announces Filing of Investigational New Drug Application for NRP409
- New River Pharmaceuticals Files New Drug Application on NRP104 for Treatment of Pediatric ADHD
- Three Rivers Pharmaceuticals Announces FDA Final Approval of Ribasphere(R) (Ribavirin, USP) Tablets 600mg, 400mg and 200mg for the Treatment of Chronic Hepatitis C
- Three Rivers Pharmaceuticals Announces FDA Tentative Approval of Ribasphere(R) (Ribavirin, USP) Tablets for the Treatment of Chronic Hepatitis C
- New River Pharmaceuticals Has 2 Drugs in Offing
 |
 |
User Comments (0)
RSS Feeds